New hope for recurrent rectal cancer: adding radiation before surgery may boost cure rates
NCT ID NCT03879109
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial studies whether adding pelvic reirradiation to chemotherapy before surgery can help more patients with locally recurrent rectal cancer achieve complete tumor removal. The study enrolls 58 adults who have had prior pelvic radiation and now face a recurrence. Participants receive either chemotherapy alone or chemotherapy followed by targeted reirradiation, then surgery. The main goal is to see which approach leads to more curative resections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chemotherapy (FOLFIRINOX) and pelvic reirradiation with capecitabine
What this could lead to
If successful, this approach could increase the chance of complete surgical removal of recurrent rectal cancer, potentially improving survival.
What could go wrong
This is a small phase 3 trial with only 58 participants, and reirradiation carries risks of side effects in previously treated pelvic areas. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Nancy
Nancy, France
-
CHU Bordeaux
Bordeaux, France
-
CHU Grenoble
Grenoble, France
-
CHU Rennes
Rennes, France
-
CHU Rouen
Rouen, France
-
CHU Toulouse
Toulouse, France
-
Centre Oscar Lambret
Lille, France
-
Groupe Hospitalier Paris Saint-Joseph
Paris, France
-
Hospices Civils de Lyon, HCL
Lyon, France
-
Institut Paoli Calmette
Marseille, France
-
Institut Sainte Catherine
Avignon, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
-
Institut du Cancer de Montpellier
Montpellier, France